Travere Therapeutics Inc (NASDAQ: TVTX) stock enjoyed a major increase of 17.6% on 12/5/23. The shares closed at $7.40. Moreover, this advance was accompanied by exceptionally high trading volume at 386% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 25.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, TVTX is expected to continue to be Value Creation neutral.
Travere Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Travere Therapeutics has a very low Power Rating of 8 and a very low Appreciation Score of 2, producing the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment